Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Update on insider trading.
https://www.secform4.com/insider-trading/1505497.htm
This Company is going nowhere
A conference? They're attending a conference and PR that? That's so OTC-ish.
I haven't started back in yet, But I have bids set (getting close) hoping to get filled soon.
I know where, but. Tell us.
I added 902. Still far from Lance's number though.
And where'd they come from?
At this time, he is holding $486,303.86 worth. Make all the fun of him ya want.
Looks like the CEO is spending large on the stock...
Acquired 200 more shares...
That was such a brutally nasty reverse split , I don't care what these Clowns think they have . I wouldn't even buy it for that ya know . I almost wonder if it would have been better if the bankruptcy turned out differently. Sorry I can't remember his name but , the guy trying to take over the ip might have been better with it , idk . I feel this is just a bunch of BS since then . Glad I made a profit barely and got out
Back when this was otc, Should had never bought more, Brtxq days
I would applaud that ...
It's a buy @ $1.75 I willing to wait since they screwed shareholder's with there last R/S
GO BRTX SEE YA UNDER $2
10Q shows about $18M left in cash, but burning $4.7M or so per quarter. That's about a year before they'll have to solicit more capital, trial not started just yet.
Let's go BRTX will be buying as soon as we go into the low $2's and it will happen
Go BRTX
I do the same ... so while I'm buying it is a sell ...:)
Cool. Those get recorded as "sells" in the history books.
Strange... most of the time I buy at the bid... or better place a bid and wait till it goes off. So I guess I buy at the bid that way.
Well, insiders still buying, so I'm doing the same
LMAO! Subliminal messaging! Watch out for the distractions!
Understanding the difference between the bid and the ask is hardly a manipulative distraction.
I'm glad I wasn't one of the many mathematically challenged in the class. It sure made it a lot easier to master the stock market, by avoiding all the manipulative distractions.
Not for me, I understand the difference between the bid and the ask, no confusion at all.
Understanding the difference between a buy at the ask and a sell into the bid is trading 101. Literally the simplest thing one must understand.
Next I guess we'll have to explain the difference between market and limit orders.
Sells or Buys, that is the question.
Doesn't really matter until Lance can "show us the money"!
If I was Lance, I think I would stop posting news...LOL
The ihub trades page has a question mark category in addition to the buy and sell categories for a reason.
All or nothing orders can execute at a price between the visible bids and asks.
Additionally, block orders can execute at different prices and then be reported as an average, which often times does not reflect the current bid or ask. This is why you sometimes see more digits in a price than there should be and why a price outside of the current bid and ask can even be reported.
See, some of us do actually understand these things.
Everyone with any math sense knows that's just a ploy to misinform unsuspecting people to get them to sell low and buy high!
So why is it that no one knows what to call the transactions that go off between the bid and ask but don't hit either?
There is a difference between sells into the bid and buys at the ask. That is why ihub differentiates between them on the trades page.
Anyone claiming there is no difference whatsoever is either clueless or trying to push something on those who do not know better.
Oh, please... Same old OTC crap rationalization.
Sells are at the bid, buys are at the ask, everybody knows that. There were twice as many sells as buys today.
Again, literally impossible! Every trade has a buy and sell matched, therefore there are exactly the same number of buys as there are sells!
Where's ProAdviser at , no words of wisdom on this tankapotomus ?
Yeah, you're right, poor choice of words on my part. It was just a comment on the ratio of sells to buys, over 2 to 1 right now.
That's literally impossible if there is actually trade volume!
Even the announcement of patient enrollment is being ignored by buyers (but not sellers).
It will happen.
I will be buy when we go under $3 or even better under $2
Go BRTX Go work your Magic L/A
Just more "sell on the news" with the markets...LOL
I've noted that we tend to be trading in the $3.20 to $4.50 range of late.
Don't understand why the price is going down. Anyhow I added today.
Nice to see Lance lining up the ducks here with BRTX.
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22 2022 - 07:30AM
GlobeNewswire Inc.
Alert
Print
Tweet Share On Facebook
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative’s second clinical trial contract executed.
BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
“With the signing of our second clinical trial agreement, we are pleased to welcome Dr. Richard Rauck who will be the principal investigator for The Center for Clinical Research,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “Dr. Rauck has extensive clinical experience and brings expertise in the field of cell-based regenerative medicine, which is invaluable for a successful clinical trial.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Form S3 out.
At the same time insiders keep on buying.
So, something is going on. Would not be surprised one of the major pharma players is going to join or will buy us.
I'll take 2s ...
The insider buying only goes so far, the stink on this is still strong. A guy will be able to buy this in the 2’s yet….
They keep on buying their own stock, hence ... I'm doing the same
BRTX: Share Structure
Authorized Shares
75,000,000
12/06/2021
Outstanding Shares
3,637,219
05/09/2022
Restricted
309,173
12/06/2021
Unrestricted
3,206,602
12/06/2021
-- First Site Will Enroll First Patient in the Clinical Study--
MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.
BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
“Currently there are no approved, cell-based therapies for cLDD. While there is encouraging data that suggests that patients with cLDD could benefit from autologous stem cell transplants, the low oxygen micro-environment of the disc makes cell-based therapies challenging. BRTX-100 is manufactured under low oxygen conditions and engineered to survive this environment,” said Scott Bainbridge, M.D., Principal Investigator for the BRTX-100 trial at The Denver Spine and Pain Institute. “Positive proof-of-concept data in this trial could be disruptive and support the potential applicability of BRTX-100 to other spine and musculoskeletal disorders where low oxygen micro-environments are found.”
“We are pleased to initiate the first of several sites across the United States that will be enrolling for the trial,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “Our sites have been carefully reviewed and selected and have clinical expertise in treating patients who could potentially benefit from BRTX-100. We look forward to working with the principal investigators and their clinical trial teams.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
You are not alone.
Followers
|
481
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
63377
|
Created
|
11/16/07
|
Type
|
Free
|
Moderators |
We will need to obtain a significant amount of financing to initiate and complete our clinical trials and implement our business plan.
Since our inception, we have not generated revenues from our operations and have funded our operations through the sale of our equity securities and debt securities. The implementation of our business plan, as discussed in this prospectus under the caption “Business,” will require the receipt of sufficient equity and/or debt financing to purchase necessary equipment, technology and materials, fund our clinical trials and other research and development efforts and otherwise fund our operations. We anticipate that we will require approximately $12,000,000 in financing to complete a Phase 2 clinical trial using BRTX-100. We anticipate that we will require approximately $45,000,000 in further additional funding to complete our clinical trials using BRTX-100 (assuming the receipt of no revenues). We will also require a substantial amount of additional funding to implement our other programs described in this prospectus under the caption “Business,” including our metabolic ThermoStem Program, and fund general operations. The net proceeds of this offering will not be sufficient to satisfy the foregoing needs. No assurance can be given that the anticipated amounts of required funding are correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no assurance can be given that we will be able to obtain any required financing on commercially reasonable terms or otherwise. In the event we do not obtain the financing required for the above purposes, we may have to curtail our development, marketing and promotional activities, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations and liquidate.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |